Developer docs
API playgroundTry for free, no card

Search company profiles

Trisk Bio

Full company profile

uuid0008vxy

Namestring
Trisk Bio
Legal namestring
Trisk Bio
Websiteurl
triskbio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Trisk Bio is a privately held contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) production for preclinical gene therapy programs. The company operates manufacturing facilities in Stevenage, United Kingdom (headquarters at 5 Gunnels Wood Park) and Waltham, Massachusetts, employing 1–10 people. Founded in 2020, Trisk Bio focuses exclusively on fully scalable AAV manufacturing workflows spanning research-grade (1e13 vg) through non-human primate (NHP) grade (5e13–1e15 vg) production for all capsids and transgenes, eliminating the need for process redesign between scales.

The company's core service is bespoke Custom AAV Manufacturing, supported by four integrated sub-offerings: high-throughput optimization workflows that screen multiple capsid variants against a single transgene; custom process development preceding large-batch manufacturing; partial capsid purification for use as analytical reference material (for ddPCR, AUC, CD-MS, and viral genome sequencing controls); and analytical development. A 2026 integration of NanoMosaic's Tessie analytics platform into Trisk's workflows at both facilities is intended to enhance analytical precision and regulatory compliance. Trisk Bio also participates in Dyno Therapeutics' expanded Frontiers Program as the first manufacturing partner, manufacturing AI-engineered capsids including Dyno-yp2 for CNS delivery.

Trisk Bio generates revenue through project-based, quote-based B2B contract manufacturing engagements with gene therapy developers. Pricing is not publicly disclosed and varies with manufacturing scale, capsid type, transgene complexity, and analytical requirements, with project structures described as multi-year contracts. The company acquires customers via direct enterprise engagement initiated through its website, industry conferences such as Dyno's Genetic Agency Technology Conference, and referral channels through technology partners and capsid developers. Only one external funding event is disclosed, a seed round with Quiet Capital in January 2022, with no reported revenue figure.

Short descriptiontext

Trisk Bio is a UK- and US-based contract manufacturer specializing in fully scalable preclinical AAV gene therapy manufacturing, serving biotech and pharma developers with research-grade to NHP-grade production, capsid optimization, and analytical services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV contract manufacturing, gene therapy manufacturing, preclinical viral vector production, capsid optimisation services, biopharmaceutical CDMO
Industry6 codes
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Contract Manufacturing (AAV / Gene Therapy CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AAV Contract Manufacturing
TypeProfessional Services
Description

Trisk Bio generates revenue through contract manufacturing services for AAV gene therapies. Services include research grade AAV production (1e13 vg), NHP grade production (5e13-1e15 vg), custom process development, analytical development, and high-throughput optimization. Revenue is project-based and scales with manufacturing batch size and complexity.

triskbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Research Grade AAV Manufacturing - 1e13 vg scale
ModelOtherBilling cadenceMulti-year contract
Notes

Custom quote-based pricing for research grade AAV production at 1e13 vg scale

triskbio.com
2NHP Grade AAV Manufacturing - 5e13 to 1e15 vg scale
ModelOtherBilling cadenceMulti-year contract
Notes

Custom quote-based pricing for non-human primate grade AAV production at 5e13-1e15 vg scale, following optimization and process development phases

triskbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Trisk Bio provides contract manufacturing of preclinical adeno-associated virus (AAV) vectors for gene therapy developers. Services span research grade (1e13 vg) to NHP grade (5e13–1e15 vg) AAV production for all capsids and transgenes, alongside custom process development, high-throughput capsid optimisation, and purification of partial capsid species for analytical reference material.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Achieved greater than 94% neuronal transduction and 11-fold improvement in brain biodistribution with Dyno-yp2 capsid
+1 more record
Product overview1 text field

Trisk Bio provides custom AAV manufacturing as a single unified service focused on bespoke scalable preclinical manufacturing of gene therapies. The core Custom AAV Manufacturing service combines four integrated sub-products: AAV Projects (encompassing high throughput optimisation, custom process development, and analytical development), Rapid optimisation workflows for capsid-transgene pair screening, Purify partials for reference material isolation, and Custom process development for scalable large batch manufacturing. Together these support all capsids and transgenes across research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production.

Product and service5 records
1Custom AAV Manufacturing
CategoryAAV Contract Manufacturing
Description

Bespoke scalable preclinical AAV manufacturing service covering research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production for all capsids and transgenes, enabling affordable preclinical manufacturing for biotech and pharma gene therapy developers.

2Rapid Optimisation Workflows
CategoryProcess Optimisation Services
Description

High throughput workflow enabling testing of a single transgene across multiple capsid variants with bespoke condition development for capsid and transgene pairs, supporting early discovery assessment and rapid progression to NHP studies.

3Custom Process Development
CategoryProcess Development Services
Description

Process development service ahead of large batch manufacturing, featuring high throughput upstream optimisation, upstream and downstream optimisation, and large batch manufacturing (1–4e14 vg NHP grade) using dPCR and mass photometry readouts.

4Purify Partials
CategoryAnalytical Reference Material Services
Description

Purification service for isolating partially filled AAV capsids for use as reference material, supporting analytical method development including spike-ins for viral genome sequencing, ddPCR, AUC, CD-MS, and advanced safety, potency, and stability studies.

5AAV Projects
CategoryProject-Based AAV Manufacturing Services
Description

Integrated service offering encompassing high throughput optimisation, custom process development, and analytical development for AAV gene therapy manufacturing, addressing Preclinical Discovery, Analytical Development, and Process Development teams.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-11
Description

Partnership to integrate NanoMosaic's Tessie analytics platform into Trisk Bio's AAV process workflows at facilities in Stevenage, England and Waltham, Massachusetts. The integration aims to enhance analytical precision and regulatory compliance for gene therapy manufacturing operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Strategic manufacturing partnership establishing Trisk Bio as the first partner in Dyno Therapeutics' expanded Frontiers Program. This partnership connects gene therapy developers with Trisk's scalable, high-purity AAV production services for Dyno's AI-engineered capsids. The collaboration aims to accelerate gene therapy development and reduce costs for developers using Dyno's capsid technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Yposkesi
TypeDirect peer
Description

France-based CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy, with cGMP-compliant production suites. Directly comparable to Trisk Bio as an AAV-focused gene therapy CDMO serving European and US biotech clients.

TypeDirect peer
Description

AAV CDMO offering scalable viral vector manufacturing services for gene therapy, with platforms supporting multiple serotypes. Comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers globally.

TypeBroad incumbent
Description

Major manufacturer of plasmids, proteins, and viral vectors (including AAV) for gene therapy developers, now part of Danaher. Comparable to Trisk Bio as an AAV-focused manufacturing services provider, but with significantly broader portfolio and GMP commercial-scale capability.

TypeDirect peer
Description

US-based viral vector CDMO focused on AAV and lentiviral manufacturing for gene and cell therapy developers, with preclinical through clinical cGMP capabilities. Directly comparable to Trisk Bio's AAV-focused CDMO model.

TypeDirect peer
Description

European (Finland-based) AAV and biopharmaceutical CDMO offering viral vector manufacturing from development through GMP production. Comparable to Trisk Bio as a Europe-based AAV CDMO, though with broader GMP clinical-stage capability.

TypeDirect peer
Description

US-based gene therapy CDMO offering end-to-end AAV and lentiviral manufacturing from process development through cGMP clinical production. Directly comparable to Trisk Bio as an AAV-focused CDMO targeting gene therapy developers, with broader clinical-stage scope.

TypeBroad incumbent
Description

Large global CDMO with mammalian, microbial, and viral vector (including AAV) manufacturing services across preclinical, clinical, and commercial stages. Comparable as an AAV contract manufacturer with broader service portfolio and established GMP credentials that Trisk Bio lacks.

TypeDirect peer
Description

AAV and lentiviral CDMO based in San Sebastian, Spain (an AskBio subsidiary) offering scalable viral vector manufacturing from preclinical through clinical stages. Directly comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers, but with significantly larger capacity and GMP clinical-stage capability.

TypeEmerging player
Description

Custom vector design and manufacturing services company offering AAV, lentiviral, and other viral vectors at research and preclinical scales. Comparable to Trisk Bio as a custom AAV service provider, though broader across vector types and with more of a catalog/research-vector emphasis.

TypeBroad incumbent
Description

Global CDMO with gene therapy viral vector manufacturing capabilities via Paragon Bioservices, serving AAV developers from preclinical through commercial. Comparable to Trisk Bio as an AAV manufacturing services provider, but with vastly larger scale, GMP clinical/commercial capability, and broader customer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trisk Bio

Biopharmaceutical Contract Manufacturing (AAV / Gene Therapy CDMO)triskbio.com

Trisk Bio is a UK- and US-based contract manufacturer specializing in fully scalable preclinical AAV gene therapy manufacturing, serving biotech and pharma developers with research-grade to NHP-grade production, capsid optimization, and analytical services.

What Trisk Bio does

Trisk Bio is a privately held contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) production for preclinical gene therapy programs. The company operates manufacturing facilities in Stevenage, United Kingdom (headquarters at 5 Gunnels Wood Park) and Waltham, Massachusetts, employing 1–10 people. Founded in 2020, Trisk Bio focuses exclusively on fully scalable AAV manufacturing workflows spanning research-grade (1e13 vg) through non-human primate (NHP) grade (5e13–1e15 vg) production for all capsids and transgenes, eliminating the need for process redesign between scales.

The company's core service is bespoke Custom AAV Manufacturing, supported by four integrated sub-offerings: high-throughput optimization workflows that screen multiple capsid variants against a single transgene; custom process development preceding large-batch manufacturing; partial capsid purification for use as analytical reference material (for ddPCR, AUC, CD-MS, and viral genome sequencing controls); and analytical development. A 2026 integration of NanoMosaic's Tessie analytics platform into Trisk's workflows at both facilities is intended to enhance analytical precision and regulatory compliance. Trisk Bio also participates in Dyno Therapeutics' expanded Frontiers Program as the first manufacturing partner, manufacturing AI-engineered capsids including Dyno-yp2 for CNS delivery.

Trisk Bio generates revenue through project-based, quote-based B2B contract manufacturing engagements with gene therapy developers. Pricing is not publicly disclosed and varies with manufacturing scale, capsid type, transgene complexity, and analytical requirements, with project structures described as multi-year contracts. The company acquires customers via direct enterprise engagement initiated through its website, industry conferences such as Dyno's Genetic Agency Technology Conference, and referral channels through technology partners and capsid developers. Only one external funding event is disclosed, a seed round with Quiet Capital in January 2022, with no reported revenue figure.

Trisk Bio firmographics

Firmographics
Name
Trisk Bio
Legal name
Trisk Bio
Website
https://triskbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Trisk Bio is a UK- and US-based contract manufacturer specializing in fully scalable preclinical AAV gene therapy manufacturing, serving biotech and pharma developers with research-grade to NHP-grade production, capsid optimization, and analytical services.
Ownership category
akta.pro rank

Trisk Bio industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (AAV / Gene Therapy CDMO)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV contract manufacturing
  • Gene therapy manufacturing
  • Preclinical viral vector production
  • Capsid optimisation services
  • Biopharmaceutical CDMO

Where Trisk Bio is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Trisk Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. AAV Contract Manufacturing: Trisk Bio generates revenue through contract manufacturing services for AAV gene therapies. Services include research grade AAV production (1e13 vg), NHP grade production (5e13-1e15 vg), custom process development, analytical development, and high-throughput optimization. Revenue is project-based and scales with manufacturing batch size and complexity.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractResearch Grade AAV Manufacturing - 1e13 vg scale
OtherMulti-year contractNHP Grade AAV Manufacturing - 5e13 to 1e15 vg scale

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Trisk Bio product offering

Product offering

Core offering

Trisk Bio provides contract manufacturing of preclinical adeno-associated virus (AAV) vectors for gene therapy developers. Services span research grade (1e13 vg) to NHP grade (5e13–1e15 vg) AAV production for all capsids and transgenes, alongside custom process development, high-throughput capsid optimisation, and purification of partial capsid species for analytical reference material.

Product overview

Trisk Bio provides custom AAV manufacturing as a single unified service focused on bespoke scalable preclinical manufacturing of gene therapies. The core Custom AAV Manufacturing service combines four integrated sub-products: AAV Projects (encompassing high throughput optimisation, custom process development, and analytical development), Rapid optimisation workflows for capsid-transgene pair screening, Purify partials for reference material isolation, and Custom process development for scalable large batch manufacturing. Together these support all capsids and transgenes across research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production.

Differentiator

Problem solved

Functional benefit

Products and services

  • Custom AAV Manufacturing Bespoke scalable preclinical AAV manufacturing service covering research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production for all capsids and transgenes, enabling affordable preclinical manufacturing for biotech and pharma gene therapy developers.
  • Rapid Optimisation Workflows High throughput workflow enabling testing of a single transgene across multiple capsid variants with bespoke condition development for capsid and transgene pairs, supporting early discovery assessment and rapid progression to NHP studies.
  • Custom Process Development Process development service ahead of large batch manufacturing, featuring high throughput upstream optimisation, upstream and downstream optimisation, and large batch manufacturing (1–4e14 vg NHP grade) using dPCR and mass photometry readouts.
  • Purify Partials Purification service for isolating partially filled AAV capsids for use as reference material, supporting analytical method development including spike-ins for viral genome sequencing, ddPCR, AUC, CD-MS, and advanced safety, potency, and stability studies.
  • AAV Projects Integrated service offering encompassing high throughput optimisation, custom process development, and analytical development for AAV gene therapy manufacturing, addressing Preclinical Discovery, Analytical Development, and Process Development teams.

Quantifiable outcome

  • Achieved greater than 94% neuronal transduction and 11-fold improvement in brain biodistribution with Dyno-yp2 capsid
  • +1 more outcomes

Companies that use Trisk Bio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Trisk Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Trisk Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • NanoMosaic, Inc.coreTechnology or Integration · 11 May 2026Partnership to integrate NanoMosaic's Tessie analytics platform into Trisk Bio's AAV process workflows at facilities in Stevenage, England and Waltham, Massachusetts. The integration aims to enhance analytical precision and regulatory compliance for gene therapy manufacturing operations.
  • Dyno TherapeuticscoreStrategic or Co-development Partner · 11 November 2025Strategic manufacturing partnership establishing Trisk Bio as the first partner in Dyno Therapeutics' expanded Frontiers Program. This partnership connects gene therapy developers with Trisk's scalable, high-purity AAV production services for Dyno's AI-engineered capsids. The collaboration aims to accelerate gene therapy development and reduce costs for developers using Dyno's capsid technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Trisk Bio competitors and assessment

Company assessment

Direct peers

  • Yposkesi: France-based CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy, with cGMP-compliant production suites. Directly comparable to Trisk Bio as an AAV-focused gene therapy CDMO serving European and US biotech clients.
  • PackGene Biotech: AAV CDMO offering scalable viral vector manufacturing services for gene therapy, with platforms supporting multiple serotypes. Comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers globally.
  • Genezen: US-based viral vector CDMO focused on AAV and lentiviral manufacturing for gene and cell therapy developers, with preclinical through clinical cGMP capabilities. Directly comparable to Trisk Bio's AAV-focused CDMO model.
  • Biovian: European (Finland-based) AAV and biopharmaceutical CDMO offering viral vector manufacturing from development through GMP production. Comparable to Trisk Bio as a Europe-based AAV CDMO, though with broader GMP clinical-stage capability.
  • Forge Biologics: US-based gene therapy CDMO offering end-to-end AAV and lentiviral manufacturing from process development through cGMP clinical production. Directly comparable to Trisk Bio as an AAV-focused CDMO targeting gene therapy developers, with broader clinical-stage scope.
  • Viralgen Vector Core: AAV and lentiviral CDMO based in San Sebastian, Spain (an AskBio subsidiary) offering scalable viral vector manufacturing from preclinical through clinical stages. Directly comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers, but with significantly larger capacity and GMP clinical-stage capability.

Broad incumbents

  • Aldevron (Danaher): Major manufacturer of plasmids, proteins, and viral vectors (including AAV) for gene therapy developers, now part of Danaher. Comparable to Trisk Bio as an AAV-focused manufacturing services provider, but with significantly broader portfolio and GMP commercial-scale capability.
  • AGC Biologics: Large global CDMO with mammalian, microbial, and viral vector (including AAV) manufacturing services across preclinical, clinical, and commercial stages. Comparable as an AAV contract manufacturer with broader service portfolio and established GMP credentials that Trisk Bio lacks.
  • Catalent (Paragon Bioservices): Global CDMO with gene therapy viral vector manufacturing capabilities via Paragon Bioservices, serving AAV developers from preclinical through commercial. Comparable to Trisk Bio as an AAV manufacturing services provider, but with vastly larger scale, GMP clinical/commercial capability, and broader customer base.

Emerging players

  • VectorBuilder: Custom vector design and manufacturing services company offering AAV, lentiviral, and other viral vectors at research and preclinical scales. Comparable to Trisk Bio as a custom AAV service provider, though broader across vector types and with more of a catalog/research-vector emphasis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Trisk Bio social profiles

Digital presence

Trisk Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trisk Bio leadership team

Management profile

Number of profiles

Trisk Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trisk Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trisk Bio

What does Trisk Bio do?

Trisk Bio provides contract manufacturing of preclinical adeno-associated virus (AAV) vectors for gene therapy developers. Services span research grade (1e13 vg) to NHP grade (5e13–1e15 vg) AAV production for all capsids and transgenes, alongside custom process development, high-throughput capsid optimisation, and purification of partial capsid species for analytical reference material.

Is Trisk Bio a public or private company?

Trisk Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Trisk Bio founded?

Trisk Bio was founded in 2020. It employs 1 to 10 people.

Where is Trisk Bio based?

Trisk Bio is headquartered in London, United Kingdom, in the Europe region.

How does Trisk Bio make money?

One revenue line is on record: AAV Contract Manufacturing.

Who are Trisk Bio's main competitors?

Direct peers on record are Yposkesi, PackGene Biotech, Genezen, Biovian, Forge Biologics and Viralgen Vector Core. Broad incumbents are Aldevron (Danaher), AGC Biologics and Catalent (Paragon Bioservices). VectorBuilder is listed as an emerging player.

Does Trisk Bio have an API?

No public API is recorded for Trisk Bio.

What industry is Trisk Bio in?

Trisk Bio's product category is Biopharmaceutical Contract Manufacturing (AAV / Gene Therapy CDMO). Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogTrisk Bio and NanoMosaic Announce Partnership for Advanced AAV AnalyticsTrisk Bio Ltd and NanoMosaic, Inc. announced a partnership to integrate NanoMosaic's Tessie analytics platform into Trisk's AAV process workflows in Stevenage, England, and Waltham, Massachusetts. The partnership aims to enhance analytical precision and regulatory compliance for gene therapy manufacturing.BioSpaceDyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers ProgramDyno Therapeutics and Trisk Bio announced a strategic manufacturing partnership through the expanded Dyno Frontiers Program, making Trisk Bio the first official manufacturing partner. This collaboration aims to provide gene therapy developers with immediate access to scalable AAV capsid manufacturing, thereby reducing technical barriers and accelerating clinical progress. The initiative seeks to lower development costs and mitigate execution risks for therapeutic candidates targeting rare diseases.DynotxDyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers ProgramDyno Therapeutics and Trisk Bio announced a strategic partnership during Dyno's Genetic Agency Technology Conference in Boston, making Trisk Bio the first Frontiers Manufacturing Partner in Dyno's expanded Frontiers Program. The partnership establishes an integrated developer-manufacturer network designed to reduce execution risk for gene therapy developers and accelerate progress toward genetic agency by combining Dyno's AI-powered AAV capsids with Trisk's scalable manufacturing capabilities. Dyno is actively seeking additional manufacturing and CRO partners to expand the ecosystem with the goal of reducing gene therapy development costs and enabling treatments for rare and ultra-rare diseases.Business Wire BlogDyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers ProgramDyno Therapeutics and Trisk Bio announced a strategic partnership during Dyno's Genetic Agency Technology Conference in Boston, with Trisk becoming the first Frontiers Manufacturing Partner in Dyno's expanded Frontiers Program. The partnership establishes an integrated developer-manufacturer network that provides gene therapy developers with access to Dyno's AI-powered AAV capsids combined with Trisk's scalable manufacturing expertise. The program aims to remove technical barriers and reduce costs that have historically slowed gene therapy development and limited patient impact.